A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
Running, not enrolling · Phase 2 · Has a placebo group
Conditions studied: Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
In brief
The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.
Key facts
- Study ID
- NCT05621317
- Run by
- Aravax Pty Ltd
- People needed
- 90
- Starts
- 2023-02-09
- Expected to finish
- 2027-06-01
- Last updated by the study team
- 2025-10-15
Who can join
Age: 4 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Arkansas Children's Research Institute — Little Rock, Arkansas, United States
- Peninsula Research Associates — Rolling Hills Estates, California, United States
- Children's Healthcare of Atlanta — Atlanta, Georgia, United States
- Riley Children's Hospital at IU — Indianapolis, Indiana, United States
- Johns Hopkins Hospital — Baltimore, Maryland, United States
- IAA Clinical Research — Chevy Chase, Maryland, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States
- Sydney Children's Hospital — Randwick, New South Wales, Australia
- The Children's Hospital at Westmead — Westmead, New South Wales, Australia
- Queensland Children's Hospital — South Brisbane, Queensland, Australia
- Women's and Children's Hospital — North Adelaide, South Australia, Australia
- The Royal Children's Hospital Melbourne — Parkville, Victoria, Australia
- Perth Children's Hospital — Nedlands, Western Australia, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.